Journal of Microbiology, Immunology and Infection
Volume 45, Issue 1 , Pages 1-6 , February 2012

Role of moxifloxacin for the treatment of commmunity-acquired complicated intra-abdominal infections in Taiwan

  • Yeu-Jun Lau

      Affiliations

    • Division of Infectious Diseases, Department of Internal Medicine, Show-Chwan Memorial Hospital, Changhua, Taiwan
    • ,
  • Yen-Hsu Chen

      Affiliations

    • Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
    • ,
  • Ching-Tai Huang

      Affiliations

    • Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan
    • ,
  • Wen-Sen Lee

      Affiliations

    • Division of Infectious Diseases, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
    • ,
  • Cheng-Yi Liu

      Affiliations

    • Division of Infectious Diseases, Department of Internal Medicine, Taipei Veteran General Hospital, Taipei, Taiwan
    • ,
  • Jien-Wei Liu

      Affiliations

    • Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital at Kaohsiung, Taiwan
    • ,
  • Hsiao-Dong Liu

      Affiliations

    • Division of General Surgery, Department of Surgery, En Chu Kong Hospital, Xinbai, Taiwan
    • ,
  • Yuarn-Jang Lee

      Affiliations

    • Division of Infectious Diseases, Department of Internal Medicine, Taipei Medical University Hospital, Taiwan
    • ,
  • Chao-Wen Chen

      Affiliations

    • Division of Trauma, Department of Emergency, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
    • ,
  • Wen-Chien Ko

      Affiliations

    • Division of Infectious Diseases, Department of Internal Medicine, National Cheng Kung University Medical College and Hospital, Tainan, Taiwan
    • ,
  • Po-Ren Hsueh

      Affiliations

    • Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
    • Corresponding Author InformationCorresponding author. Departments of Laboratory Medicine and Internal Medicine, National Taiwan University College of Medicine, 7 Chung Shan South Road, Taipei 100, Taiwan.

Received 24 October 2011 ,Revised 3 November 2011 ,Accepted 10 November 2011.

References 

  1. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:133–164
  2. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt). 2010;11:79–109
  3. Hsueh PR, Hawkey PM. Consensus statement on antimicrobial therapy of intra-abdominal infections in Asia. Int J Antimicrob Agents. 2007;30:129–133
  4. Liu CD, McFadden DW. Acute abdomen and appendix. In:  Greenfield LJ,  Mulholland MW,  Oldham KT,  Zelenock GB editor. Surgery: scientific principles and practice. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1997;p. 1246–1261
  5. Marshall JC. Intra-abdominal infections. Microbes Infect. 2004;6:1015–1025
  6. Solomkin JS, Hemsell DL, Sweet R, Tally F, Bartlett J. Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992;15(suppl. 1):S33–S42
  7. Goldstein EJ, Snydman DR. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J Antimicrob Chemother. 2004;53(suppl. 2):ii29–ii36
  8. Evans HL, Raymond DP, Pelletier SJ, Crabtree TD, Pruett TL, Sawyer RG. Diagnosis of intra-abdominal infection in the critically ill patient. Curr Opin Crit Care. 2001;7:117–121
  9. Mazuski JE, Sawyer RG, Nathens AB, DiPiro JT, Schein M, Kudsk KA, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg Infect. 2002;3:161–173
  10. Blot S, De Waele JJ. Critical issues in the clinical management of complicated intra-abdominal infections. Drugs. 2005;65:1611–1620
  11. Goldstein EJ. Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents. Clin Infect Dis. 2002;35(Suppl 1):S106–S111
  12. Malangoni MA, Song J, Herrington J, Choudhri S, Pertel P. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg. 2006;244:204–211
  13. Chow JW, Satishchandran V, Snyder TA, Harvey CM, Friedland IR, Dinubile MJ. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect (Larchmt). 2005;6:439–448
  14. Chen YH, Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, et al. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J Infect. 2011;62:280–291
  15. Chen WY, Jang TN, Huang CH, Hsueh PR. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections at a medical center in Taiwan: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) 2002–2006. J Microbiol Immunol Infect. 2009;42:317–323
  16. Edmiston CE, Krepel CJ, Seabrook GR, Somberg LR, Nakeeb A, Cambria RA, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother. 2004;48:1012–1016
  17. Liu CY, Lu CL, Huang YT, Liao CH, Hsueh PR. In vitro activities of moxifloxacin and tigecycline against bacterial isolates associated with intra-abdominal infections at a medical center in Taiwan, 2001–2006. Eur J Clin Microbiol Infect Dis. 2009;28:1437–1442
  18. Liu CY, Huang YT, Liao CH, Yen LC, Lin HY, Hsueh PR. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother. 2008;52:3161–3168
  19. Krobot K, Yin D, Zhang Q, Sen S, Altendorf-Hofmann A, Scheele J, et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis. 2004;23:682–687
  20. Stein GE, Schooley S, Tyrrell KL, Citron DM, Nicolau DP, Goldstein EJ. Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens. Anaerobe. 2008;14:8–12
  21. Wirtz M, Kleeff J, Swoboda S, Halaceli I, Geiss HK, Hoppe-Tichy T, et al. Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother. 2004;53:875–877
  22. Stass H, Rink AD, Delesen H, Kubitza D, Vestweber KH. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother. 2006;58:693–696
  23. Wacke R, Forster S, Adam U, Mundkowski RG, Klar E, Hopt UT, et al. Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. J Antimicrob Chemother. 2006;58:994–999
  24. Rink AD, Stass H, Delesen H, Kubitza D, Vestweber KH. Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess. Clin Drug Investig. 2008;28:71–79
  25. Weiss G, Reimnitz P, Hampel B, Muehlhofer E, Lippert H. AIDA Study Group. Moxifloxacin for the treatment of patients with cIAI, the AIDA study. J Chemother. 2009;21:170–180
  26. Solomkin J, Zhao YP, Ma EL, Chen MJ, Hampel B. DRAGON study team. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents. 2009;34:439–445
  27. De Waele J, Tellado J, Alder J, Reimnitz P, Jensen M, Hampel B, et al. Efficacy and safety of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study. Vienna, Austria: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2010;Abstract P1549
  28. Goldstein EJ, Solomkin JS, Citron DM, Alder JD. Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin. Clin Infect Dis. 2011 Oct 12;Epub

PII: S1684-1182(11)00211-8

doi: 10.1016/j.jmii.2011.11.010

Journal of Microbiology, Immunology and Infection
Volume 45, Issue 1 , Pages 1-6 , February 2012

Article Tools

* Image Usage & Resolution